These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice. Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286 [TBL] [Abstract][Full Text] [Related]
4. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. Watanabe D; Hashimoto S; Ishiai M; Matsushita M; Baba Y; Kishimoto T; Kurosaki T; Tsukada S J Biol Chem; 2001 Oct; 276(42):38595-601. PubMed ID: 11507089 [TBL] [Abstract][Full Text] [Related]
5. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
6. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Smith CIE; Burger JA Front Immunol; 2021; 12():689472. PubMed ID: 34177947 [TBL] [Abstract][Full Text] [Related]
7. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. Tomlinson MG; Woods DB; McMahon M; Wahl MI; Witte ON; Kurosaki T; Bolen JB; Johnston JA BMC Immunol; 2001; 2():4. PubMed ID: 11410123 [TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Hsu J; Gu Y; Tan SL; Narula S; DeMartino JA; Liao C Immunol Lett; 2013 Feb; 150(1-2):97-104. PubMed ID: 23266841 [TBL] [Abstract][Full Text] [Related]
9. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity. Middendorp S; Dingjan GM; Maas A; Dahlenborg K; Hendriks RW J Immunol; 2003 Dec; 171(11):5988-96. PubMed ID: 14634110 [TBL] [Abstract][Full Text] [Related]
10. B cell receptor signaling down-regulates forkhead box transcription factor class O 1 mRNA expression via phosphatidylinositol 3-kinase and Bruton's tyrosine kinase. Hinman RM; Bushanam JN; Nichols WA; Satterthwaite AB J Immunol; 2007 Jan; 178(2):740-7. PubMed ID: 17202334 [TBL] [Abstract][Full Text] [Related]
11. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428 [TBL] [Abstract][Full Text] [Related]
12. Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function. Kurosaki T; Kurosaki M J Biol Chem; 1997 Jun; 272(25):15595-8. PubMed ID: 9188445 [TBL] [Abstract][Full Text] [Related]
13. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794 [TBL] [Abstract][Full Text] [Related]
14. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427 [TBL] [Abstract][Full Text] [Related]
16. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling. Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133 [TBL] [Abstract][Full Text] [Related]
17. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645 [TBL] [Abstract][Full Text] [Related]
18. Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling. Hashimoto S; Iwamatsu A; Ishiai M; Okawa K; Yamadori T; Matsushita M; Baba Y; Kishimoto T; Kurosaki T; Tsukada S Blood; 1999 Oct; 94(7):2357-64. PubMed ID: 10498607 [TBL] [Abstract][Full Text] [Related]